Radiotherapy for Prostate Cancer

(DESTINATION 2 Trial)

This trial aims to test a new radiotherapy approach for men with intermediate-risk, localized prostate cancer. It compares two methods of delivering radiotherapy using advanced imaging technology. The focus is on the treatment's impact on prostate cancer control and the side effects experienced by patients. Men diagnosed with prostate cancer who require prostate radical radiotherapy and meet specific criteria, such as having a tumor visible on an MRI scan, may qualify for this trial. As an unphased trial, this study offers patients the chance to contribute to pioneering research that could enhance future prostate cancer treatments.

The trial does not specify if you need to stop taking your current medications. However, you can continue taking androgen deprivation therapy (ADT) if it's part of your standard care.

Research has shown that prostate cancer treatment with radical radiotherapy is generally safe and well-tolerated, even at varying dose levels. Studies have found that higher daily doses are both safe and effective. Notably, a large study discovered that a shorter course of radiation with standard doses is as effective as longer treatments.

Another study highlighted that increasing the radiation dose was well-tolerated, with only a small percentage of patients experiencing serious side effects. Specifically, only 1% to 2.3% of patients had severe long-term issues with their digestive or urinary systems.

Researchers are excited about this trial because it explores the potential of using tailored radiotherapy doses for prostate cancer, which could lead to more personalized treatments. Unlike the standard uniform dose approach, the "De-escalated dose" arm targets the benign prostate tissue with a lower dose while focusing a higher dose specifically on the tumor mass, potentially reducing side effects and sparing healthy tissue. The "Uniform dose" arm serves as a comparison to evaluate the effectiveness of this targeted strategy. This trial aims to find out if these innovative dosing methods can maintain treatment efficacy while minimizing harm to surrounding healthy tissue, offering new hope for improved cancer care.

This trial will compare two radiotherapy approaches for prostate cancer. Research has shown that radiotherapy can effectively treat prostate cancer. In this trial, one group will receive a de-escalated dose; past data suggested that the chances of the cancer not returning after 2 and 3 years were 58% and 46%, respectively. The other group will receive a uniform dose throughout treatment, which has shown benefits in controlling the disease over time. Both methods aim to manage prostate cancer effectively, balancing treatment effects with possible side effects.¹⁶⁷⁸⁹